{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=5", "query": { "intervention": "Control/Placebo group", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 5227, "total_pages": 523, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T08:01:24.958Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05062759", "title": "Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Asthma" ], "interventions": [ { "name": "Tezepelumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Years to 21 Years" }, "enrollment_count": 70, "start_date": "2021-08-23", "completion_date": "2022-07-18", "has_results": true, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 15, "location_summary": "Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Northfield", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05062759" }, { "nct_id": "NCT00852696", "title": "Over Active Bladder Patients Having Sling Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "Solifenacin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Cleveland Clinic Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 1, "start_date": "2008-02", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 1, "location_summary": "Weston, Florida", "locations": [ { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00852696" }, { "nct_id": "NCT01517373", "title": "Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04937319 10 mg", "type": "DRUG" }, { "name": "PF-04937319 50 mg", "type": "DRUG" }, { "name": "PF-04937319 100 mg", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 304, "start_date": "2012-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 23, "location_summary": "Roseville, California • San Diego, California • Walnut Creek, California + 17 more", "locations": [ { "city": "Roseville", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517373" }, { "nct_id": "NCT03220737", "title": "VAXCHORA Pediatric Study to Assess Safety and Immunogenicity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cholera (Disorder)" ], "interventions": [ { "name": "VAXCHORA (Cholera Vaccine, Live, Oral)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 550, "start_date": "2017-07-21", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 10, "location_summary": "Atlanta, Georgia • Lenexa, Kansas • Wichita, Kansas + 7 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220737" }, { "nct_id": "NCT00668772", "title": "Tiotropium/Salmeterol Inhalation Powder in COPD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Tiotropium/Salmeterol", "type": "DRUG" }, { "name": "Salmeterol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 207, "start_date": "2008-04-15", "completion_date": "2008-11-21", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 16, "location_summary": "Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668772" }, { "nct_id": "NCT05048875", "title": "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "Cohort 1 - Group 1 JNJ High Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 2 JNJ Medium Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 2 JNJ Low Dose", "type": "DRUG" }, { "name": "Cohort 1 - Group 1/2 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2022-02-03", "completion_date": "2024-09-10", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Burlington, Vermont", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05048875" }, { "nct_id": "NCT02865928", "title": "Serratus Plane Block for Postoperative Pain Control", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Outpatient Breast Surgery", "Mastopexy", "Augmentation", "Revision" ], "interventions": [ { "name": "Bupivicaine HCl", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 42, "start_date": "2017-09-05", "completion_date": "2019-11-25", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02865928" }, { "nct_id": "NCT05358886", "title": "A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "BPN14770/ zatolmilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tetra Discovery Partners", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 171, "start_date": "2022-11-01", "completion_date": "2025-07-18", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 17, "location_summary": "Irvine, California • Orange, California • Sacramento, California + 14 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05358886" }, { "nct_id": "NCT03798405", "title": "Reactive vs. Proactive Pain Control in IBD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Diseases", "Pain", "Opioid Use", "Crohn Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Proactive Analgesic Inpatient Narcotic-Sparing", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-01-01", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798405" }, { "nct_id": "NCT04551066", "title": "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis", "Post Polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "parsaclisib", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-05-24", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-11-09T08:01:24.958Z", "location_count": 36, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551066" } ] }